Science and Enterprise

Tag: equity

  • European Venture Volume Up, Science Company Investments Drop

    Venture capital (VC) investment volume rose in the second quarter of 2012 compared to the second quarter of 2011, but the number of VC deals dropped sharply. The number and volume of investments in European science-based companies, says financial industry research service Dow Jones VentureSource, declined by double-digit percentages in the second quarter of 2012…

  • $2.6B Venture Fund Aims for Health Care, Energy Companies

    New Enterprise Associates Inc., a venture capital company in Chevy Chase, Maryland, says it has closed its 14th fund with $2.6 billion in capital. New Enterprise says the new fund is its third consecutive property exceeding $2.5 billion, and brings the company’s total committed capital to more than $13 billion across all of its funds.…

  • Biopharma Secures $38.5 Million in Series D Funds

    Chiasma Inc., a biopharmaceutical company in Jerusalem, Israel, has closed its $38.5 million series D funding round, the fourth cycle of financing after initial start-up. The round was led by by new investor Abingworth and current investor MPM Capital, with participation from current share holders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures, and…

  • University, Company to Collaborate on Cancer Imaging

    Queen’s University in Belfast, Northern Ireland, U.K., is partnering with start-up company Cirdan Imaging Ltd., also in Northern Ireleand, to develop new imaging tools for the detection and treatment of cancer. As part of the deal, QUBIS Ltd., the university’s technology transfer subsidiary, will take an equity stake in Cirdan Imaging. The agreement involves research…

  • VC Funding Cut for U.S. Firms, Science Companies Take Hit

    Venture capital investments in U.S.-based companies are down for the second quarter of 2012, with software and Internet companies favored over enterprises based on scientific discoveries. According to Dow Jones VentureSource, a financial industry research service, companies in the U.S. raised $8.1 billion in 863 deals during the second quarter of 2012, a nine percent…

  • Chronic Pain Technology Company Gains $3.5M Series B Funds

    Neuros Medical Inc., a company in Cleveland developing a university-discovered electronic pain relief technology, says it raised $3.5 million in series B venture funds, the second round of financing after start-up. Boston Scientific and Glengary LLC led the round, with new investors RiverVest Venture Partners, LLC, Blue Tree Allied Angels, and ModelVest joining current investors…

  • Renewable Chemicals Developer Raises $104M in Venture Funds

    Elevance Renewable Sciences in Woodbridge, Illinois says it raised $104 million in its series E financing, the fifth round of funding after start-up. Lacustrine Limited, a subsidiary of Genting Berhad, based in Kuala Lumpur, Malaysia led the round with Total Energy Ventures International, based in Paris. Elevance produces specialty chemicals for personal care products, detergents,…

  • Venture Investors Increase First Half 2012 Fund Raising

    Venture capital (VC) funds in Europe and the U.S. have increased their fund raising in the first half of 2012 by double-digit percentages, according to Dow-Jones LP Source, a financial industry research service. More fund raising by VCs indicates potentially more financing available for start-up companies liked those backed by venture investors. LP Source says…

  • Luminex Corp. Acquires Molecular Diagnostics Developer

    Luminex Corporation, a maker of medical diagnostics technologies in Austin, Texas will acquire Hayward, California-based GenturaDx, a developer of genomic testing systems. The $50 million deal involves Luminex purchasing all outstanding shares in the privately-owned GenturaDx. Luminex develops and manufactures instruments, software, reagents, and assays used in clinical labs as well as in pharmaceutical, diagnostic,…

  • Bristol-Myers Squibb Buys Amylin, Expands AstraZenca Deal

    The pharmaceutical company Bristol-Myers Squibb in Princeton, New Jersey will acquire diabetes drug maker Amylin Pharmaceuticals in San Diego, California for $31.00 per share or $5.3 billion. Bristol-Myers Squibb will also expand its current collaboration with pharmaceutical maker AstraZeneca in London developing diabetes drugs, using the assets acquired through Amylin. Amylin Pharmaceuticals is expected to…